8.955
price down icon2.77%   -0.255
pre-market  Pre-market:  8.95   -0.005   -0.06%
loading
Eyepoint Pharmaceuticals Inc stock is traded at $8.955, with a volume of 1.39M. It is down -2.77% in the last 24 hours and down -18.96% over the past month. EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$9.21
Open:
$9.14
24h Volume:
1.39M
Relative Volume:
1.87
Market Cap:
$611.19M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-3.1755
EPS:
-2.82
Net Cash Flow:
$-1.61M
1W Performance:
-16.78%
1M Performance:
-18.96%
6M Performance:
-26.24%
1Y Performance:
+26.66%
1-Day Range:
Value
$8.70
$9.155
1-Week Range:
Value
$8.25
$10.83
52-Week Range:
Value
$5.855
$30.99

Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile

Name
Name
Eyepoint Pharmaceuticals Inc
Name
Phone
617-926-5000
Name
Address
480 PLEASANT STREET, WATERTOWN, MA
Name
Employee
144
Name
Twitter
@eyepointpharma
Name
Next Earnings Date
2024-11-08
Name
Latest SEC Filings
Name
EYPT's Discussions on Twitter

Compare EYPT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
EYPT 8.955 611.19M 46.02M -70.80M -1.61M -2.82
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-22-24 Initiated JP Morgan Overweight
Nov-02-23 Initiated Mizuho Buy
Apr-21-23 Initiated Robert W. Baird Outperform
Jul-07-22 Initiated Chardan Capital Markets Buy
Mar-01-21 Initiated Cowen Outperform
Jan-28-21 Initiated Cantor Fitzgerald Overweight
Apr-06-20 Downgrade B. Riley FBR Buy → Neutral
Nov-04-19 Resumed Laidlaw Buy
Sep-12-19 Initiated Guggenheim Buy
View All

Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News

pulisher
Nov 20, 2024

EYPT (EyePoint Pharmaceuticals) Enterprise Value : $396.54 Mil (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

EyePoint Pharmaceuticals (FRA:PV3B) Enterprise Value : €374.46 Mil (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 18, 2024

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register

Nov 18, 2024
pulisher
Nov 18, 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

EyePoint Pharmaceuticals Awards 23,600 Stock Options to New Employees at $9.17 | EYPT Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 16, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 8.5%What's Next? - MarketBeat

Nov 16, 2024
pulisher
Nov 14, 2024

EyePoint Pharmaceuticals : Announces $16.5 Million Monetization of ILUVIEN Royalty with SWK Holdings Corporation - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

HC Wainwright Has Pessimistic View of EYPT FY2024 Earnings - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha

Nov 14, 2024
pulisher
Nov 13, 2024

Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

EyePoint price target lowered to $33 from $38 at Baird - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

(EYPT) Technical Data - Stock Traders Daily

Nov 12, 2024
pulisher
Nov 12, 2024

EyePoint Pharmaceuticals Reports $29.4 Million Third Quarter Net Loss - Vision Monday

Nov 12, 2024
pulisher
Nov 11, 2024

EyePoint shares retain Outperform as Baird sees upside in DME and wet AMD opportunities - Investing.com

Nov 11, 2024
pulisher
Nov 11, 2024

EyePoint Pharmaceuticals, Inc.’s US$161 Million Public Offering Of Common Stock - Global Legal Chronicle

Nov 11, 2024
pulisher
Nov 11, 2024

H.C. Wainwright trims EyePoint stock target, highlights cash runway extension to 2027 - Investing.com

Nov 11, 2024
pulisher
Nov 11, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $22.00 by Analysts at HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $33.00 by Analysts at Robert W. Baird - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $33.00 - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance Australia

Nov 09, 2024
pulisher
Nov 08, 2024

EyePoint Pharmaceuticals Advances in Retinal Therapeutics - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

EyePoint Pharmaceuticals: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 07, 2024
pulisher
Nov 07, 2024

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments - The Manila Times

Nov 07, 2024
pulisher
Nov 06, 2024

Federated Hermes, Inc. Expands Stake in EyePoint Pharmaceuticals Inc - GuruFocus.com

Nov 06, 2024
pulisher
Nov 05, 2024

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Scrip

Nov 05, 2024
pulisher
Nov 05, 2024

With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in EyePoint Pharmaceu - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5.4%What's Next? - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 03, 2024

EyePoint Pharmaceuticals Announces Successful Closure of Underwritten Public Offering WATERTOWN, Mass., October 31, 2024 – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) recently finalized its underwritten public offering of 14,636,363 shares - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

EYPTEyePoint Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

When (EYPT) Moves Investors should Listen - Stock Traders Daily

Nov 01, 2024
pulisher
Oct 31, 2024

EyePoint rises on interim data for mid-stage trial of its diabetic macular edema therapy - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

EyePoint Pharmaceuticals prices $140M share offering - MSN

Oct 31, 2024
pulisher
Oct 30, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? - MSN

Oct 30, 2024
pulisher
Oct 29, 2024

Guggenheim maintains Buy on EyePoint with $68 target - Investing.com India

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - The Manila Times

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewswire Inc.

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.5%Should You Sell? - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint launches $100 million public stock offering By Investing.com - Investing.com Australia

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Reaffirmed by Chardan Capital - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52% - Simply Wall St

Oct 29, 2024
pulisher
Oct 29, 2024

‘Really competitive’ tax breaks keep EyePoint manufacturing in Mass. - The Business Journals

Oct 29, 2024
pulisher
Oct 29, 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Oct 29, 2024

Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):